Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes

Takumi Hirata, Kouichi Inukai, Jiro Morimoto, Shigehiro Katayama, Hitoshi Ishida

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Aims We investigated to clarify factors associated with the efficacy of sitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor, for glycemic control including the confounding effect of concomitant drugs in patients with type 2 diabetes. Methods We included type 2 diabetes patients with HbA1c levels of ≥ 7% who were not under insulin treatment and were administered sitagliptin (50 mg/day for 6 months). Reduction or discontinuation of insulin sensitizers was not permitted during the study period. Outcomes included HbA1c level variations and attaining a target HbA1c level of <7%. Associated factors with each outcome were examined using multivariate analysis. Results Of the 313 patients enrolled in this study, 147 (47.0%) attained HbA1c levels of <7%. High baseline HbA1c levels were associated with HbA1c level variations but inversely associated with attaining the target HbA1c level of <7%. Concomitant use of an insulin sensitizer and a α-glucosidase inhibitor and maintenance of the baseline dose of concomitant drugs were significantly associated with each outcome. Conclusions Our results suggest that concomitant sitagliptin administration (50 mg/day) will improve glycemic control if treatment is initiated before HbA1c levels deteriorate. Other medication should be continued at initiation of sitagliptin administration.

Original languageEnglish
Pages (from-to)265-270
Number of pages6
JournalPrimary Care Diabetes
Volume8
Issue number3
DOIs
Publication statusPublished - 2014 Oct

Keywords

  • Concomitant drugs
  • Glycemic control
  • Sitagliptin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Fingerprint

Dive into the research topics of 'Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes'. Together they form a unique fingerprint.

Cite this